Repligen Corporation's Upcoming Conference Attendance
Repligen Corporation (NASDAQ: RGEN), a leading life sciences organization, specializes in bioprocessing technology. The company has recently announced its participation in several notable investor conferences. These conferences provide invaluable opportunities for networking and engagement with various stakeholders in the biopharmaceutical industry.
The UBS Global Healthcare Conference
Scheduled from November 10 to 12, Repligen's Chief Financial Officer, Jason Garland, will join an analyst-led discussion on November 10 at 11:00 a.m. ET. This event promises to provide insights into the company's strategic direction and innovative solutions.
The Stifel Healthcare Conference
Following UBS, Repligen will be represented at the Stifel Healthcare Conference from November 11 to 13. Olivier Loeillot, the President and CEO, is slated to participate in an analyst discussion at 10:00 a.m. ET on November 11. This gathering aims to foster connections with investors and industry experts.
Wolfe Research Healthcare Conference
On the radar next is the Wolfe Research Healthcare Conference, occurring from November 17 to 19. CFO Jason Garland will engage in another discussion on November 18 at 12:40 p.m. ET. Repligen views this as a chance to showcase its advancements in the bioprocessing domain.
Jefferies Global Healthcare Conference
Repligen is also set to attend the Jefferies Global Healthcare Conference from November 18 to 20 in London. Here, Olivier Loeillot will participate in an analyst-led panel on November 18 at 8:30 a.m. ET/1:30 p.m. GMT. This conference represents a significant platform for Repligen to highlight their ongoing innovations.
Wrapping Up with the Stephens Annual Investment Conference
The final conference on Repligen's calendar is the Stephens Annual Investment Conference, occurring between November 18 and 20. Jason Garland will be involved in a series of one-on-one meetings with investors on November 19, discussing Repligen's future trajectory and financial health.
Webcast Accessibility
A live webcast of the presentations will be offered on Repligen's website, providing further engagement for those interested in the discussions. This is a great opportunity for investors and analysts unable to attend in person.
About Repligen Corporation
Repligen Corporation leads in designing and commercializing innovative bioprocessing technologies that enhance the efficiency of biological drug manufacturing. With a mission of inspiring advances in bioprocessing, the company primarily aids biopharmaceutical developers and Contract Development and Manufacturing Organizations (CDMOs) globally. Their main areas of expertise include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. Headquartered in Waltham, Massachusetts, Repligen operates several manufacturing sites across the U.S. and Europe.
Repligen Contact Information
For further inquiries, Jacob Johnson, VP of Investor Relations, can be reached at 781-419-0204 or via email at investors@repligen.com.
Frequently Asked Questions
What is the purpose of the investor conferences for Repligen?
The investor conferences provide platforms for Repligen to engage with investors, present its strategies, and showcase its innovative advancements in bioprocessing.
Who will represent Repligen at these conferences?
Jason Garland, the CFO, and Olivier Loeillot, the President and CEO, are the key representatives attending these events.
Where can I watch the live webcasts of the presentations?
The live webcasts will be accessible through Repligen's official website during each conference.
What does Repligen focus on as a company?
Repligen specializes in developing bioprocessing technologies that enhance the efficiency of manufacturing biological drugs.
How can I learn more about Repligen Corporation?
You can find more information on Repligen's products and innovations by visiting their official website.